Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT
Copyright © 2021 Elsevier B.V. All rights reserved..
PURPOSE: To assess the prognostic role of different inter and intralesional expression (heterogeneity) of oestrogen receptor (ER) in bone metastases, as identified by the combined use of [18F]FES PET/CT and [18F]FDG PET/CT in patients with oestrogen receptor-positive (ER+) metastatic breast cancer (BC).
METHODS: We analysed patients with a new diagnosis of bone metastases who were candidates for first-line systemic endocrine therapy. Before starting therapy, patients underwent baseline [18F]FES PET/CT and [18]FDG PET/CT. Semi-quantitative evaluation of whole-body bone metabolic burden (WB-B-MB) was performed on [18F]FES and [18F]FDG PET/CT in order to evaluate disease extent, tumour metabolism and ER heterogeneity. We used time-to-event analyses (Kaplan-Meier and Cox proportional-hazards methods) to estimate progression-free (PFS) and overall survival (OS), in order to assess the independent prognostic value of [18F]FES PET/CT and [18F]FDG PET/CT, alone and in combination.
RESULTS: According to our criteria, we enrolled 49 patients. Over a median follow-up of 44.7 months, 35 patients suffered disease progression (71.4 %) and 15 died of disease (30.6 %). When the risk of disease progression was calculated by means of the Cox model, only [18F]FDG WB-B-MB was independently and directly associated to PFS (p = 0.02). On analysing the association between all prognostic parameters and survival, the Cox model showed that the only parameter associated with OS was the WB-B-MB FES/FDG ratio (p = 0.01).
CONCLUSION: The combined use of [18F]FES-PET/CT and [18F]FDG-PET/CT can identify ER heterogeneity in BC bone metastases. This heterogeneity is significantly associated with survival. Moreover, the extension of the FDG-avid component correlates with the risk of disease progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
European journal of radiology - 141(2021) vom: 15. Aug., Seite 109821 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bottoni, Gianluca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
(18)F-FDG |
|---|
| Anmerkungen: |
Date Completed 13.07.2021 Date Revised 13.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejrad.2021.109821 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326871160 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326871160 | ||
| 003 | DE-627 | ||
| 005 | 20231225195529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejrad.2021.109821 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1089.xml |
| 035 | |a (DE-627)NLM326871160 | ||
| 035 | |a (NLM)34139575 | ||
| 035 | |a (PII)S0720-048X(21)00302-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bottoni, Gianluca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.07.2021 | ||
| 500 | |a Date Revised 13.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a PURPOSE: To assess the prognostic role of different inter and intralesional expression (heterogeneity) of oestrogen receptor (ER) in bone metastases, as identified by the combined use of [18F]FES PET/CT and [18F]FDG PET/CT in patients with oestrogen receptor-positive (ER+) metastatic breast cancer (BC) | ||
| 520 | |a METHODS: We analysed patients with a new diagnosis of bone metastases who were candidates for first-line systemic endocrine therapy. Before starting therapy, patients underwent baseline [18F]FES PET/CT and [18]FDG PET/CT. Semi-quantitative evaluation of whole-body bone metabolic burden (WB-B-MB) was performed on [18F]FES and [18F]FDG PET/CT in order to evaluate disease extent, tumour metabolism and ER heterogeneity. We used time-to-event analyses (Kaplan-Meier and Cox proportional-hazards methods) to estimate progression-free (PFS) and overall survival (OS), in order to assess the independent prognostic value of [18F]FES PET/CT and [18F]FDG PET/CT, alone and in combination | ||
| 520 | |a RESULTS: According to our criteria, we enrolled 49 patients. Over a median follow-up of 44.7 months, 35 patients suffered disease progression (71.4 %) and 15 died of disease (30.6 %). When the risk of disease progression was calculated by means of the Cox model, only [18F]FDG WB-B-MB was independently and directly associated to PFS (p = 0.02). On analysing the association between all prognostic parameters and survival, the Cox model showed that the only parameter associated with OS was the WB-B-MB FES/FDG ratio (p = 0.01) | ||
| 520 | |a CONCLUSION: The combined use of [18F]FES-PET/CT and [18F]FDG-PET/CT can identify ER heterogeneity in BC bone metastases. This heterogeneity is significantly associated with survival. Moreover, the extension of the FDG-avid component correlates with the risk of disease progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (18)F-FDG | |
| 650 | 4 | |a (18)F-FES | |
| 650 | 4 | |a Bone metastases | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Heterogeneity | |
| 650 | 4 | |a Oestrogen receptor | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Receptors, Estrogen |2 NLM | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 700 | 1 | |a Piccardo, Arnoldo |e verfasserin |4 aut | |
| 700 | 1 | |a Fiz, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Siri, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Matteucci, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Rocca, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Nanni, Oriana |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Brain, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Alberini, Jean Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Dib, Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Sacchetti, Gian Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Saggia, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Harbeck, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Wuerstlein, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Degenhardt, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a DeCensi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Rollandi, Gian Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of radiology |d 1993 |g 141(2021) vom: 15. Aug., Seite 109821 |w (DE-627)NLM012952397 |x 1872-7727 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2021 |g day:15 |g month:08 |g pages:109821 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejrad.2021.109821 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2021 |b 15 |c 08 |h 109821 | ||